Neumora Therapeutics Inc. (NASDAQ:NMRA) price closed lower on Friday, March 22, dropping -5.51% below its previous close.
A look at the daily price movement shows that the last close reads $13.98. Taking into account the 52-week price action we note that the stock hit a 52-week high of $21.00 and 52-week low of $9.35. The stock subtracted -29.81% on its value in the past month.
Neumora Therapeutics Inc., which has a market valuation of $2.10 billion. Analysts tracking NMRA have forecast the quarterly EPS to shrink by -0.34 per share this quarter, while the same analysts predict the annual EPS to hit -$1.5 for the year 2024 and up to -$1.62 for 2025. In this case, analysts estimate an annual EPS growth of 58.70% for the year and -8.00% for the next year.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with 1 upward and no downward reviews.
The overview shows that NMRA’s price is at present -21.47% off the SMA20 and -19.98% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 29.85, with weekly volatility standing at 6.49%. The indicator jumps to 8.02% when calculated based on the past 30 days. Neumora Therapeutics Inc. (NASDAQ:NMRA)’s beta value is holding at 0, while the average true range (ATR) indicator is currently reading 1.28.
An analysis of the Neumora Therapeutics Inc. (NASDAQ:NMRA) stock in terms of its daily trading volume indicates that the 3-month average is 375.41K. However, this figure increases on the past 10-day timeline to an average of 1.13 million.
Current records show that the company has 158.83M in outstanding shares. The insiders’ percentage holdings are 69.33% of outstanding shares while the percentage share held by institutions stands at 14.74%. The stats also highlight that short interest as of Feb 29, 2024, stood at 4.9 million shares, which puts the short ratio at the time at 19.66. From this we can glean that short interest is 3.09% of company’s current outstanding shares. Notably, we see that shares short in February rose slightly given the previous month’s figure stood at 4.5 million. But the -22.52% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
